Mirabegron 25mg Tablet is a prescription beta-3 adrenergic receptor agonist used to treat symptoms of overactive bladder (OAB), including urinary urgency, increased urinary frequency and urge urinary incontinence. In the United States, mirabegron is marketed under the brand Myrbetriq®, while Betmiga® is a major international brand reference.
Mirabegron 25mg is an extended-release/prolonged-release formulation. It relaxes the detrusor muscle during bladder filling, helping the bladder store urine more effectively. The 25mg strength is particularly relevant when a lower dose is appropriate based on clinical factors such as kidney or liver function, tolerability or prescribing guidance.
Mirabegron 25mg is used for symptoms associated with overactive bladder (OAB), including:
Mirabegron is a beta-3 adrenergic agonist that works differently from antimuscarinic OAB medicines.
Mirabegron 25mg for overactive bladder is the primary therapeutic and commercial search relationship for this product.
Overactive bladder can cause a frequent or sudden need to urinate and may result in involuntary urine leakage. Mirabegron activates beta-3 receptors in the bladder, helping relax the detrusor muscle during the storage phase.
This can increase functional bladder capacity and reduce some OAB symptoms.
Urinary urgency is a characteristic symptom of overactive bladder.
By promoting bladder muscle relaxation, mirabegron can help reduce involuntary contractions and improve the ability to delay urination.
People with OAB may experience urinary frequency, sometimes together with urgency or urge incontinence.
Mirabegron is specifically used to manage these OAB symptoms.
Mirabegron for urge urinary incontinence is an important treatment and search term.
Urge incontinence occurs when a sudden, difficult-to-control need to urinate results in involuntary urine leakage. Mirabegron can improve bladder storage function and help reduce OAB-related urgency and leakage.
Mirabegron is a selective beta-3 adrenergic receptor agonist.
It activates beta-3 adrenergic receptors in the detrusor smooth muscle of the bladder. This promotes relaxation during bladder filling and increases the bladder’s ability to store urine.
Unlike antimuscarinic medicines, mirabegron does not primarily work by blocking muscarinic receptors.
Myrbetriq® is a brand-name mirabegron product.
Generic mirabegron contains the same active ingredient, although the manufacturer, inactive ingredients, packaging and regulatory status may differ.
Where the appropriate regulatory approval exists, Generic Myrbetriq 25mg is a commercially important search term for generic mirabegron 25mg.
Use “Generic Myrbetriq” for a particular product only where its regulatory status supports the generic/equivalent claim in the target market.
Betmiga® is another major brand reference for mirabegron used in several international markets.
For commercial SEO, the product relationship can be structured as:
Mirabegron 25mg → Generic Mirabegron 25mg → Generic Myrbetriq 25mg → Betmiga 25mg
The exact reference brand and generic terminology should correspond to the regulatory status of the product in each target country.
Mirabegron is available in 25mg and 50mg extended-release formulations.
In the US prescribing information, 25mg once daily is the recommended starting dose for adult overactive bladder, with an increase to 50mg once daily based on individual response and tolerability. Dose limitations apply to certain patients with renal or hepatic impairment.
The appropriate dose should be determined by the prescribing healthcare professional.
Do not increase from 25mg to 50mg without medical advice.
Mirabegron extended-release tablets are generally taken orally once daily according to the prescription.
The extended-release tablet should be swallowed whole. It should not be crushed, split or chewed unless the specific product information states otherwise.
Take mirabegron according to the instructions provided with the prescribed product.
Possible adverse effects include:
Not everyone experiences side effects.
Seek medical advice if adverse effects are persistent, severe or concerning.
Mirabegron can increase blood pressure.
Blood pressure should be assessed before treatment and monitored as clinically appropriate. Patients with severe uncontrolled hypertension may not be suitable for mirabegron.
People with hypertension should discuss their blood pressure history with their healthcare professional before starting treatment.
Mirabegron should be used cautiously in patients with bladder outlet obstruction or when used together with certain antimuscarinic medicines because urinary retention can occur.
Patients with difficulty emptying the bladder should seek appropriate medical evaluation before treatment.
Mirabegron can affect the metabolism of certain medicines because it is a moderate CYP2D6 inhibitor.
This may increase exposure to some CYP2D6-substrate medicines. Clinically important interactions can therefore occur with selected medicines, particularly those with a narrow therapeutic index.
Tell your healthcare professional about all prescription medicines, over-the-counter medicines and supplements you take.
Kidney function can affect the appropriate mirabegron dose.
Patients with significant renal impairment may require a dose limitation or may not be appropriate candidates for certain strengths.
A healthcare professional should determine the appropriate strength based on renal function and the prescribing information applicable to the product.
Patients with liver impairment may require a lower dose or may have restrictions on mirabegron use depending on the severity of hepatic impairment.
Tell your healthcare professional if you have liver disease before treatment.
Overactive bladder becomes more common with age, and mirabegron may be prescribed to older adults when clinically appropriate.
Age alone does not determine the appropriate dose. Kidney function, liver function, blood pressure, other medicines and overall health should be considered.
Mirabegron 25mg Tablet has strong product-level commercial intent around overactive bladder treatment and generic alternatives to Myrbetriq®.
High-intent searches include:
Mirabegron 25mg Tablet, Mirabegron 25mg, Mirabegron 25mg Extended Release, Generic Mirabegron 25mg, Generic Myrbetriq 25mg, Myrbetriq 25mg Generic, Mirabegron 25mg for Overactive Bladder, Mirabegron 25mg for Urinary Urgency, Mirabegron 25mg for Urge Incontinence, Mirabegron 25mg Price and Mirabegron 25mg Online.
Prescription status, generic availability, approved indications, manufacturer availability and import requirements vary by country.
Mirabegron 25mg is used to treat symptoms of overactive bladder, including urinary urgency, urinary frequency and urge urinary incontinence.
Myrbetriq® is a brand-name mirabegron product. A generic mirabegron product contains the same active ingredient, but manufacturer and inactive ingredients can differ.
Yes. Generic mirabegron extended-release 25mg products are available in markets where the relevant regulatory approvals have been granted.
Betmiga® is a brand reference for mirabegron in several international markets. A specific generic product should only be described as equivalent to a reference brand where its regulatory status supports that claim.
Mirabegron 25mg treats symptoms associated with overactive bladder, particularly urinary urgency, increased frequency and urge urinary incontinence.
Mirabegron activates beta-3 adrenergic receptors in the bladder, relaxing the detrusor muscle during bladder filling and helping increase bladder storage capacity.
No. Mirabegron is a treatment for bladder symptoms, not hypertension. In fact, mirabegron can increase blood pressure.
Yes. Mirabegron 25mg is the lower commonly marketed extended-release strength. The appropriate dose depends on the patient’s clinical circumstances.
Some patients may be prescribed 50mg after starting at 25mg, depending on response, tolerability, kidney function and liver function. Dose changes should only be made by the prescribing healthcare professional.
Mirabegron can be prescribed with solifenacin in certain patients with overactive bladder. Combination treatment should only be used when specifically prescribed and monitored by a healthcare professional.
Some improvement may occur during the first several weeks, while the full therapeutic effect can take longer. Individual response varies.
Yes. Mirabegron is a prescription medicine in major markets such as the United States and United Kingdom.
It may be used long term when clinically appropriate and tolerated. Continued treatment should be periodically reviewed by a healthcare professional.
Mirabegron is a prescription medicine. Online purchases should be made only through an appropriately licensed pharmacy or authorized supplier and according to local regulations.
Mirabegron is marketed in multiple international markets, although brand names, generic availability, prescription requirements and approved indications can vary.
Medical Disclaimer: This product information is provided for educational and informational purposes only and is not a substitute for professional medical advice, diagnosis or treatment. Mirabegron is a prescription medicine and should be used according to the prescribing information applicable to the specific product and country. It can increase blood pressure and may contribute to urinary retention in susceptible patients. Patients with kidney disease, liver disease, hypertension or complex medication regimens should consult a qualified healthcare professional before treatment. Do not start, stop or change mirabegron treatment without appropriate medical supervision.
Last Updated: August 25, 2026
Orders ship from our India Head Office within 1–2 business days of confirmation. We include full customs documentation — HS codes, certificates of origin, and pharmaceutical export permits.
Estimated delivery: 3–7 business days to UK. 7–10 business days to UAE, Saudi Arabia and Gulf countries. 10–15 days for USA and Asian countries.
All packages arrive in plain, unmarked brown boxes. No pharmacy name or medication details on the outside.
Mirabegron 25mg Tablet
Reviews
There are no reviews yet